c/tirzepatide wiki

What this community is for

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

c/tirzepatide was created on 9 Aug 2023 and currently has 187,300 members and 130 captured submissions. It sits in the busiest tier of the site, which mostly affects how fast a question gets answered rather than how well.

Rules, and why each exists

Community rules come first, then the six site-wide rules that apply everywhere on GLP Research Hub. Community rules are enforced by the moderators listed at the bottom of this page; site rules are enforced by everyone.

1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.

And the site rules, which are short on purpose:

1. Independent community. Nobody here sells anything, and anyone who tries is banned.
2. Not medical advice. Describe what you did; never prescribe to a stranger.
3. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
4. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
5. No contact handles, wallet addresses or tracking numbers — they identify people.
6. Be recognisably decent. Disagree hard, insult nobody.

Terms you will see

Vocabulary that turns up constantly in c/tirzepatide. Each links to the topic page, which collects every submission that touches it.

• tirzepatide — dual GIP/GLP-1 receptor agonist; the SURMOUNT and SURPASS programme drug.
• Mounjaro — discussed frequently in this community — see the topic page for every submission that touches it.
• Zepbound — discussed frequently in this community — see the topic page for every submission that touches it.
• GIP — discussed frequently in this community — see the topic page for every submission that touches it.
• SURMOUNT — discussed frequently in this community — see the topic page for every submission that touches it.
• SURPASS — discussed frequently in this community — see the topic page for every submission that touches it.
• 15mg — discussed frequently in this community — see the topic page for every submission that touches it.
• dual agonist — discussed frequently in this community — see the topic page for every submission that touches it.

Start here

The twelve highest-scoring submissions in this community. Not necessarily the most correct — the most agreed-with, which is a different thing, and worth remembering when you read them.

1. GIP: the version I wish someone had shown me in week 1 — 15k points, 13 comments, 2 years ago
2. [Lab] split one vial across VendorInvestigate and PeptideMeter — 98.0% and 99.0% — 13k points, 39 comments, 2 years ago
3. anyone else notice SURMOUNT kicking in around week 80 — 12k points, 63 comments, 1 year ago
4. am I the only one who found GIP harder than the injections — 11k points, 47 comments, 1 year ago
5. nobody warned me about injection-site soreness and I would have liked the warning — 11k points, 47 comments, 1 year ago
6. am I the only one who found Mounjaro harder than the injections — 10k points, 47 comments, 2 years ago
7. [Results] 57 weeks, 20kg, and tirzepatide was the hard part — 9.3k points, 35 comments, 2 years ago
8. three years of Mounjaro threads, summarised so you do not have to read them — 8.5k points, 64 comments, 2 years ago
9. my ApoB moved and I cannot work out whether tirzepatide is why — 7.7k points, 20 comments, 1 year ago
10. small win: GIP stopped being a problem at week 81 — 7.4k points, 27 comments, 2 years ago
11. [Vendor] QST order #6 — Denmark, 3 days, no drama, receipts inside — 7.4k points, 70 comments, 2 years ago
12. [Lab] 13th independent test on BCH, and the trend is the interesting part — 7.3k points, 37 comments, 2 years ago

Asked constantly

• 2.5 → 5 → 7.5 in six weeks was a mistake, here is what happened
• my resting HR went from 58 to 66 on titration and settled back
• [Question] does the vial concentration change how much dead space costs me
• [Question] how do you actually verify Mounjaro
• small win: GIP stopped being a problem at week 31
• [Question] Sweden — has anyone got a straight answer on GIP
• switched from 1.0mg to 2.5mg and the the food-noise thing got better, not worse
• what changed for me between week 15 and week 58
• tried tirzepatide for 23 weeks. here is what happened.
• [Question] Australia — has anyone got a straight answer on dual agonist

If your question is on that list, read the answers there first. If it is not, ask it — that is what the community is for, and "this has been asked" is only a helpful reply when it comes with a link.

Who runs this

Moderation here is done by volunteers who also post as normal members. They are not clinicians, not vendors, and not paid.

• u/titration_marshal — c/semaglutide mod. No, you should not jump to 2.4 in week three.
• u/incretin_ivy — GIP/GLP-1 co-agonism is genuinely interesting pharmacology, separate from the weight story.
• u/quiet_moderator — I remove the obvious stuff so you never see it. Message the modmail, not me.
• u/dexa_twice_yearly — Two DEXA scans a year. Lean mass held at 92% while fat mass halved. Resistance training.